Compare Moody's Corporation (MCO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Moody's Corporation trades at $490.77 (market cap $88.28B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: Moody's Corporation is far larger — about 57.7× Recursion Pharmaceuticals Inc's market cap, and Moody's Corporation pays a 0.82% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MCO | RXRX | |
|---|---|---|
Market Cap | $88.28B | $1.53B |
Sector | Financials | Health |
52-Week High | $539.61 | $6.79 |
52-Week Low | $412.23 | $2.84 |
Enterprise Value | $94.08B | $946.50M |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moody's Corporation (MCO) trades at $490.54, down 3.97% in the last session, with strong fundamentals including 31.69% net income margin and 74.54% ROE. The stock shows bullish technical signals with moving averages supporting upward momentum, while recent earnings consistently beat expectations. Revenue growth has accelerated from $5.5B in 2022 to $7.7B in 2025, with Q2 2026 results expected on July 22, 2026.
MCO presents a compelling investment case with premium valuation metrics (P/E 36.25) justified by exceptional profitability and market dominance. Key risks include valuation sensitivity and dependence on debt issuance cycles. Analyst consensus remains bullish with $558.14 price target, representing 13.8% upside potential from current levels.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
